Quince Therapeutics, Inc.QNCXNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank63
3Y CAGR+4.3%
5Y CAGR-14.1%
Year-over-Year Change
Research and development spending
3Y CAGR
+4.3%/yr
vs +25.7%/yr prior
5Y CAGR
-14.1%/yr
Recent acceleration
Acceleration
-21.4pp
Decelerating
Percentile
P63
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $28.61M | +53.9% |
| 2024 | $18.59M | +96.8% |
| 2023 | $9.45M | -62.5% |
| 2022 | $25.18M | -58.6% |
| 2021 | $60.80M | -0.8% |
| 2020 | $61.31M | +102.9% |
| 2019 | $30.21M | +199.6% |
| 2018 | $10.09M | +10.8% |
| 2017 | $9.10M | - |